Market: NASD |
Currency: USD
Address: 10578 Science Center Drive
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Show more
📈 Avidity Biosciences, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$67.00
-
Upside/Downside from Analyst Target:
37.92%
-
Broker Call:
34
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-1.16
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Avidity Biosciences, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-07 | -1.21 |
| 2025-05-08 | -0.9 |
| 2025-02-27 | -0.8 |
| 2024-11-07 | -0.65 |
| 2024-08-09 | -0.65 |
| 2024-05-09 | -0.79 |
| 2024-02-28 | -0.79 |
| 2023-11-08 | -0.71 |
| 2023-08-08 | -0.66 |
| 2023-05-09 | -0.74 |
| 2023-02-28 | -0.88 |
| 2022-11-08 | -0.82 |
| 2022-08-09 | -0.92 |
| 2022-05-10 | -0.71 |
| 2022-03-01 | -0.84 |
| 2021-11-09 | -0.68 |
| 2021-08-09 | -0.7 |
| 2021-05-12 | -0.64 |
| 2021-03-15 | -0.33 |
| 2020-11-10 | -0.31 |
| 2020-08-10 | -1.23 |
📰 Related News & Research
No related articles found for "avidity biosciences".
